Group items tagged

Launch of new products is expected to propel growth of the metabolomics market. For instance, in January 2021, JUNO Metabolomics launched the JUNO Viral Surveillance Platform based on its proprietary AI-Based Informatics System. Similarly, in June 2019, Bruker Corp. presented mass spectrometry and Nuclear Magnetic Resonance systems and other solutions for molecular phenomics and clinical metabolomics research at Metabolomics 2019. Moreover, increasing prevalence of chronic disorders is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Integration of Artificial Intelligence (AI) with metabolomics is expected to offer lucrative growth opportunities for players in the metabolomics market. For instance, in July 2020, ReviveMed, an AI-driven drug discovery platform, collaborated with Bristol Myers Squibb for an AI-driven metabolomics study that will leverage ReviveMed's AI platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer. Moreover, increasing demand for metabolomics is also expected to aid in growth of the market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/integration-of-ai-with-metabolomics-and.html

The patient registry software market is expected to witness a significant growth over the next five years. The reason for this is the ever-expanding focus on healthcare delivery, particularly in the non-clinical fields of patient care, education, prevention and public health. Patient safety is being continuously refined with the advent of new devices and applications in the clinical laboratories. Certain drivers are also behind the patient registry growth. These include adoption of EHR, creation of patient registries to track patient records, and greater use of electronic medical records (EMR) for post-marketing management. Increasing prevalence of cancer and other chronic disorders is expected to propel growth of the global patient registry software market. For instance, according to the study, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/increasing-prevalence-of-cancer-and.html

Nurse call system makes an all-in one solution for both your nurse call needs as well as wireless nurse phone calls. These systems have been some of the best in the market these days in that they can incorporate any old piece of hospital equipment into a single unified call center system. With an integrated system, you can now use your pager, digital radio, or even your cell phone to dial in, and you can get live access to your nurses through a large LCD screen. Nurses can use this system at the reception desk or even while on the job. For those who wish to be constantly on the go, the system also features an LCD screen with a large touch pad that makes it easy to navigate and input data. A digital radio, headset, and other necessary hardware are all included in the package for the best experience possible. There are many options to choose from in this type of system, depending on how much you want to spend. The biggest thing to consider is how much you need and whether you want a more basic system, or a more advanced system like a fully integrated one. Each system comes with a long warranty, so if ever there was a time when you needed a system to replace, you are covered. High prevalence of chronic disorders is expected to propel growth of the global nurse call systems market. For instance, according to the study, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/high-prevalence-of-chronic-disorders-to.html

Increasing adoption of smartphones is expected to propel growth of the global online retail market. For instance, according to Pew Research Center, as of February 2019, 81% of U.S. adults used smartphones compared to 77% in October 2018. Moreover, increasing penetration of internet is also expected to aid in growth of the market. For instance, according to China government-backed Market Intelligence & Consulting Institute and reported by China Internet Watch, internet penetration in China reached 61.2 percent in the first half of 2019, with 854 million internet users at the end of June 2019. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global online retail market. For instance, in July 2020, Columbia Sportswear Company reported a 40% decline in overall net revenues in its July 2020 quarterly earnings report, due in part to pandemic-related store closures. However, the company's e-commerce sales increased 72% compared with the year-ago period. Moreover, increasing expenditure on personal care products is also expected to aid in growth of the market. For instance, according to the U.S. Bureau of Labor Statistics, average annual expenditure on personal care products in the U.S. increased from US$ 707 in 2016 to US$ 768 in 2018. Among regions, Asia Pacific is expected to witness significant growth in the online retail market. For instance, according to India Brand Equity Foundation, the e-commerce sector in India is expected to reach US$ 200 billion by 2026 from US$ 38.5 billion as of 2017. The market is also driven by significant growth in the FMCG sector. For instance, according to India Brand Equity Foundation, FMCG market in India is expected to grow at a CAGR of 27.86 per cent and is expected to reach US$ 103.70 billion by 2020 from US$ 52.75 billion in FY18. Read More @ https://coherentmarketinsights-blog.blogspot.com/2020/11/emergence-of-covid-19-to-augment-growth.html

Patient monitoring refers to the collection and analysis of medical data from one or more health settings (such as in hospitals or doctor's offices) for use by health care providers and other professionals in order to detect changes in an individual's medical status and to provide treatment options as needed. In health care, patient monitoring is generally the measurement of one or more medical parameters over extended periods of time, usually at different health care settings (such as in doctor's offices or hospitals). Patient monitoring may be implemented in many different health care settings including primary care offices, emergency rooms, doctors' offices, nursing homes, private practices, and government agencies. Most patient monitoring systems contain software that collect and store medical data in a database that is accessible to multiple health care providers and to health care facilities. High prevalence of chronic disorders is expected to propel growth of the global remote patient monitoring devices market over the forecast period. For instance, according to the study, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Read More @ https://coherentmarketinsights-blog.blogspot.com/2020/11/high-prevalence-of-chronic-disorders-to.html

We found that the MIPS 2020 and MIPS 2019 Quality measures are more similar than they are different. Nevertheless, we got into a bit of detail in this article to give you a better idea.

In MIPS 2019 and MIPS 2020, participants get to submit 6 quality measures data for 12 months (from January 1 to December 31, 2019, and January 1 to December 31, 2020, respectively). The amount of data to undergo submission depends on the collection (measure) type.

MIPS put forwards the opportunity to get incentives and bonuses aside from the regular payment model. The revenue cycle runs smoothly, and also if a clinician performs well in all MIPS performance categories, he/she can earn a reputation in the healthcare industry among fellow physicians.

MIPS 2019 performance year is about to end. Only a little time is left until eligible clinicians can report for MIPS healthcare. MIPS put forwards the opportunity to get incentives and bonuses aside from the regular payment model.

Report and review data to Medicare for the MIPS 2019 performance categories before it's too late. March 31, 2020, is the last date to do it.

Small Medical Practices! P3Care has been doing well as MIPS Qualified Registry for four years now. During this time, we come up with many little tricks to achieve a minimum performance threshold to be safe from the penalty. Read the article below to know how small practices can avoid the negative payment adjustment in MIPS 2019 reporting.

Physicians! It's time to prepare for the MIPS 2019 reporting period. There's only a little time left. This time may be hectic and stressful, even for MIPS qualified registries. But don't worry, P3 Healthcare Solutions has come up with effective tips to target high MIPS scores. Let's be honest, MIPS QPP can be a daunting approach to earn incentives for those who are not careful.

Physical therapists are included as one of the groups of healthcare practitioners eligible for MIPS reporting in 2019. It was time their duties were rewarded with an open heart and a clear head. Physical therapy is a serious branch of medicine that, now, comes in the quality circle of the government where physical therapists (PTs) can receive incentives based on their performances.

The Global Industrial Lubricants Market is expected to grow at a CAGR of 6.4% from 2019 to reach $29.79 billion by 2025. Moreover, in terms of volume, the overall industrial lubricants market is expected to grow at a CAGR of 2.3% from 2019 to reach 18,473.5 thousand tons by 2025.

Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.

Pulmonary Arterial Hypertension (PAH) is a disease that affects the vasculature of the heart, specifically the arteries that transport blood from the heart to the lungs. Common symptoms include heart palpitations or an irregular rhythm, chest pain, coughing, wheezing, shortness of breath, chest discomfort when breathing, and sometimes even heart failure. The cause of pulmonary hypertension is not known, but research has indicated that genetic and hormonal factors may play a role in its development. The growing prevalence of Pulmonary Arterial Hypertension (PAH) is driving the growth of the Pulmonary Arterial Hypertension (PAH) Market. According to the European Respiratory Society, PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million. The growing geriatric population is again increasing the prevalence of such disease which is also projected to foster the growth of the Pulmonary Arterial Hypertension (PAH) market. According to the United nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. North America is projected to gain significant growth over the forecast period and this is attributed to the growing adoption of advanced treatment for treating pulmonary arterial hypertension. Moreover, increasing spending by the government on the healthcare sector is again augmenting the regional market growth. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028. Reads more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/increasing-global-healthcare-spending.html

QPP MIPS participation offers a golden opportunity to target incentives and bonuses. Especially when the CMS has been favoring and rewarding small medical practices then why not take advantage of this chance.

CMS has always proven to be an authority that speaks in favor of clinicians and address their concerns. Due to the unfortunate situation of coronavirus outbreak, doctors and other clinicians were facing quite some issues regarding submitting data to CMS.

It is about accuracy of data for each performance category that matters the most in MIPS. As a MIPS Qualified Registry for the fourth time in a row is a living proof of our past performances and current status. In this article, we got a chance to reflect on a few MIPS data essentials; and thought they would be useful for clinicians before the submission window closes for good.

Overview: This webinar provides an overview of the MACRA legislation and developing regulations and guidelines. We'll help you understand how medical practices will be paid in the future for services to Medicare patients. You'll be asked to choose between two paths. If you choose to participate with other providers in an Advanced Payment Model, the larger organization will be paid for services provided and determine how to share those payments as well as any cost savings among the participants. If you choose the Merit-Based Incentive Payment System (MIPS), your payment rate will vary based on how you perform on a variety of Medicare Quality Programs - PQRS, VBM, Meaningful Use and a 4th new component focused on Quality Improvement. You'll want to know as much as possible about the pros and cons of each option and how to make the right choice for your practice. Why should you Attend: Under the MACRA legislation, your providers will need to choose between participating in an Advanced Payment Model (APM) or participating in the new Merit-Based Incentive Payment System. Making the wrong choice can result in significant reductions in your future Medicare payments. You'll want to understand the options and have a plan in place by January 1, 2017 - that's only 6 months away. Areas Covered in the Session: Learn the requirements of the new MACRA legislation and how it will impact your Medicare payments in 2019 and beyond Find out what you need to be doing now to ensure you don't lose Medicare revenue in future years Understand the options - APM vs MIPS - and how your Medicare payments can increase or decrease under each model Identify what aspects of the new payment methodology are written into the legislation, what has been released through proposed regulations and when final rules are expected. Who Will Benefit: Practice Administrators, CEOs, COOs Physicians and all providers who bill to Medicare Quality Officers Nurse leaders Finance Directors Speaker Pro

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

Before we go into the details, the Merit-based Incentive Payment System (MIPS) comes under the direct obligation of the Medicare Access and CHIP Reauthorization Act (MACRA), the law that regulates the incentive program across the US.